SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

NEW YORK, NY—Additional data from the PARTNER 3 trial of low-risk patients with symptomatic severe aortic stenosis (AS), as well as real-world data from the TVT Registry, suggest that ...

Please provide your email address to receive an email when new articles are posted on . At 3 years, a self-expanding TAVR valve conferred better hemodynamics vs. a balloon-expandable valve in patients ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Edwards Lifesciences is entering New York Valves 2026 armed with strong data on its transcatheter aortic valve replacement platforms. The Irvine, CA-based company presented data spanning aortic, ...

Irvine-based Edwards Lifesciences Corp. today announced newly presented data from several of its clinical trials. The data, presented at the annual New York Valves 2026 conference, included seven-year ...

Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's ...

NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which ...

At 10 years, TAVR with the second-generation balloon-expandable Sapien XT was associated with higher mortality and aortic valve reintervention than surgery in the intermediate-risk PARTNER 2A trial.

NEW YORK CITY -- It was increasingly clear that clinical trials alone won't tell the full story of how transcatheter aortic valve replacement (TAVR) performs in the real world, according to midterm ...